Clinical study on desensitization treatment of asparaginase allergy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035956

Enrollment

Unknown

Registered

2020-08-20

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphocytic leukemia

Interventions

trial group:Rituximab+Bortezomi

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1) Acute lymphocytic leukemia with the protocol CCCG-ALL-2020; 2) The patients show allergy to both PEG-asp and Erw-asp; 3) The asparaginase Cumulative dose under 75%; 4) The patient sign the informed consent form for the study.

Exclusion criteria

Exclusion criteria: 1) Contraindications of asparaginase for a variety of reasons except asparaginase allergy; 2) Contraindications of rituximab and contraindications of bortezomib.

Design outcomes

Primary

Measure	Time frame
activity of asparaginase;	—

Secondary

Measure	Time frame
titer of asparaginase antibody;titer of plasma cells;Event-free survival;overall survival;	—

Countries

China

Contacts

Public ContactChen Changcheng

Shanghai Children Medical Center

chenchangcheng@scmc.com.cn+86 15921419041

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026